
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
2 Volatile Stocks Worth Investigating and 1 to Steer Clear Of
Mon 12 May 25, 04:35 AMGuardant Health First Quarter 2025 Earnings: Beats Expectations
Fri 02 May 25, 11:17 AMQ1 2025 Guardant Health Inc Earnings Call
Thu 01 May 25, 04:04 PMGuardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Wed 30 Apr 25, 09:50 PMGuardant Health’s (NASDAQ:GH) Q1: Strong Sales, Stock Soars
Wed 30 Apr 25, 08:50 PMGuardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Wed 30 Apr 25, 08:05 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -417.54000M | -435.08900M | -478.76400M | -653.44900M | -384.47000M |
| Minority interest | - | - | 0.00000M | 0.00000M | -20.90000M |
| Net income | -416.27700M | -436.37300M | -479.44900M | -654.58800M | -384.77000M |
| Selling general administrative | 211.41M | 180.12M | 155.80M | 163.96M | 206.64M |
| Selling and marketing expenses | 494.66M | 364.94M | 295.23M | 299.83M | 191.88M |
| Gross profit | 633.01M | 449.22M | 336.90M | 293.21M | 250.74M |
| Reconciled depreciation | 39.74M | 42.39M | 42.88M | 35.96M | 22.27M |
| Ebit | -413.64300M | -432.50800M | -476.18600M | -544.37800M | -411.00100M |
| Ebitda | -373.90700M | -390.12100M | -433.30500M | -650.87200M | -381.89300M |
| Depreciation and amortization | 39.74M | 42.39M | 42.88M | -106.49400M | 29.11M |
| Non operating income net other | - | - | - | -106.49400M | 29.11M |
| Operating income | -436.29800M | -443.59400M | -564.72500M | -544.37800M | -411.00100M |
| Other operating expenses | 1419.27M | 1182.61M | 1128.67M | 993.92M | 784.65M |
| Interest expense | 3.90M | 2.58M | 2.58M | 2.58M | 2.58M |
| Tax provision | -1.26300M | 1.28M | 0.69M | 1.14M | 0.30M |
| Interest income | 34.09M | 53.69M | 35.37M | 6.07M | 3.93M |
| Net interest income | 30.20M | 51.11M | 32.79M | 3.49M | 1.35M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -1.26300M | 1.28M | 0.69M | 1.14M | 0.30M |
| Total revenue | 982.02M | 739.02M | 563.95M | 449.54M | 373.65M |
| Total operating expenses | 1070.26M | 892.81M | 901.62M | 837.59M | 661.74M |
| Cost of revenue | 349.01M | 289.80M | 227.05M | 156.32M | 122.91M |
| Total other income expense net | 18.76M | 8.51M | 85.96M | -109.07100M | 26.53M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -416.27700M | -436.37300M | -479.44900M | -654.58800M | -384.77000M |
| Net income applicable to common shares | - | - | - | -654.58800M | -405.67000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2013.66M | 1485.61M | 1786.42M | 1609.98M | 2204.50M |
| Intangible assets | 25.92M | 6.76M | 8.98M | 11.73M | 14.21M |
| Earning assets | - | - | - | - | - |
| Other current assets | 40.72M | 33.80M | 27.74M | 31.51M | 53.05M |
| Total liab | 2112.97M | 1625.26M | 1627.74M | 1549.81M | 1559.49M |
| Total stockholder equity | -99.30700M | -139.64700M | 158.68M | 60.18M | 645.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 197.53M | 122.35M | 108.26M | -21.87800M | 152.93M |
| Common stock | 0.00100M | 0.00100M | 0.00100M | 0.00100M | 0.00100M |
| Capital stock | 0.00100M | 0.00100M | 0.00100M | 0.00100M | 0.00100M |
| Retained earnings | -2994.51200M | -2578.23500M | -2141.86200M | -1662.41300M | -1007.82500M |
| Other liab | - | - | - | 9.18M | 3.93M |
| Good will | 77.26M | 3.29M | 3.29M | 3.29M | 3.29M |
| Other assets | - | - | - | 36.45M | 60.94M |
| Cash | 378.20M | 525.54M | 1133.54M | 141.65M | 492.20M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 302.73M | 225.58M | 205.92M | 193.22M | 194.69M |
| Current deferred revenue | 50.75M | 35.47M | 17.96M | 17.40M | 11.33M |
| Net debt | 1304.26M | 810.51M | 220.23M | 1227.64M | 868.67M |
| Short term debt | - | 29.21M | 27.95M | 21.88M | 12.86M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1682.46M | 1336.05M | 1353.76M | 1369.28M | 1360.87M |
| Other stockholder equity | 2900.06M | 2443.79M | 2304.22M | 1742.11M | 1657.59M |
| Property plant equipment | - | - | - | 167.92M | 313.90M |
| Total current assets | 1466.05M | 1055.11M | 1347.11M | 1191.59M | 1114.13M |
| Long term investments | - | - | - | 0.00000M | 698.03M |
| Net tangible assets | - | - | - | 45.16M | 627.51M |
| Short term investments | 823.39M | 314.44M | 35.10M | 869.58M | 440.55M |
| Net receivables | 137.85M | 110.25M | 88.78M | 97.26M | 97.65M |
| Long term debt | 1504.00M | 1142.55M | 1139.97M | 1137.39M | 1134.82M |
| Inventory | 85.88M | 71.08M | 61.95M | 51.60M | 30.67M |
| Accounts payable | 54.44M | 38.55M | 51.74M | 175.82M | 17.58M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4.85200M | -5.20100M | -3.67500M | -19.52200M | -4.76400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00100M | 0.00100M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -1662.41300M | -1007.82500M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 139.67M | 141.37M | 124.18M | 61.45M | 60.94M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 547.61M | 430.50M | 439.31M | 418.39M | 1090.37M |
| Capital lease obligations | 206.14M | 193.50M | 213.80M | 231.89M | 226.05M |
| Long term debt total | - | - | - | 1137.39M | 1134.82M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -519.90800M | -261.30800M | 247.42M | 149.82M | 51.30M |
| Change to liabilities | - | - | - | 9.87M | 37.57M |
| Total cashflows from investing activities | -627.20200M | -261.30800M | 840.25M | 149.82M | -63.15500M |
| Net borrowings | 402.50M | 0.00000M | 0.00000M | -0.07100M | -0.78400M |
| Total cash from financing activities | 671.13M | -0.99600M | 477.38M | -189.09300M | -66.82400M |
| Change to operating activities | - | - | - | 11.91M | 0.43M |
| Net income | -416.27700M | -436.37300M | -479.44900M | -654.58800M | -384.77000M |
| Change in cash | -140.33800M | -503.93200M | 991.74M | -842.62800M | -340.68900M |
| Begin period cash flow | 629.75M | 1133.69M | 141.95M | 492.29M | 832.98M |
| End period cash flow | 489.42M | 629.75M | 1133.69M | -350.34000M | 492.29M |
| Total cash from operating activities | -184.76000M | -239.85800M | -324.97500M | -309.46300M | -209.01700M |
| Issuance of capital stock | 345.00M | 0.00000M | 493.12M | - | 0.00000M |
| Depreciation | 39.74M | 42.39M | 42.88M | 35.96M | 22.27M |
| Other cashflows from investing activities | - | - | 1.53M | -23.96600M | -39.42200M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -14.79200M | -9.13500M | -10.35000M | -20.92600M | -7.95700M |
| Change to account receivables | -28.17500M | -21.38900M | 8.38M | 0.38M | -44.35300M |
| Sale purchase of stock | 13.59M | 11.72M | 10.15M | 9.32M | 9.75M |
| Other cashflows from financing activities | 569.68M | -15.83400M | -15.74100M | -200.96300M | -76.43100M |
| Change to netincome | - | - | - | 104.27M | 153.88M |
| Capital expenditures | 48.31M | 35.09M | 20.49M | 77.46M | 75.03M |
| Change receivables | - | - | - | 0.38M | -44.35300M |
| Cash flows other operating | - | - | - | 208.41M | -1.06900M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -348.74000M | -338.99600M |
| Change in working capital | 9.78M | -60.86200M | 53.84M | 61.56M | -40.46800M |
| Stock based compensation | 166.22M | 140.41M | 90.76M | 94.69M | 151.45M |
| Other non cash items | 15.78M | 74.58M | -33.00600M | 152.91M | 29.61M |
| Free cash flow | -233.06600M | -274.94300M | -345.46100M | -386.92400M | -284.05200M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GH Guardant Health Inc |
-3.14 2.41% | 127.03 | - | - | 12.07 | 55.67 | 12.68 | -5.404 |
| TMO Thermo Fisher Scientific Inc |
-8.13 1.69% | 473.95 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
1.97 1.12% | 178.08 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
2.35 1.74% | 137.40 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
9.91 1.80% | 560.73 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Palo Alto, California.
3100 Hanover Street, Palo Alto, CA, United States, 94304
| Name | Title | Year Born |
|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 1979 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 1980 |
| Mr. Michael Bell | Chief Financial Officer | 1969 |
| Mr. John G. Saia | Chief Legal Officer | 1973 |
| Dr. Craig Eagle M.D. | Chief Medical Officer | 1967 |
| Mr. Christopher Freeman | Chief Commercial Officer of Oncology Bus. | 1974 |
| Mr. Andy Ament | Sr. VP of Operations | NA |
| Darya Chudova | Sr. VP of Technology | NA |
| Mr. Kumud Kalia | Chief Information Officer | NA |
| Ms. Jennifer Higgins | VP of Public Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.